December 06, 2020 Corporate News

• San Diego Harley-Davidson Team Welcomes New Owner, Established Racecar Driver and Motorcycle Enthusiast Acquires Eighth Dealership
•  
• Novartis analyses confirm benefit of Kymriah® with clinically meaningful rates of complete response seen in patients with certain advanced lymphomas
•  
• Lancement de la première étude d'immunothérapie cellulaire UniCAR sur les tumeurs solides avancées
•  
• Sysmex Inostics Presents Data at the American Society of Hematology Annual Meeting Demonstrating Exquisite Sensitivity of SafeSEQ NGS Technology for Detection of Measurable Residual Disease in Acute Myeloid Leukemia
•  
• Sumitomo Dainippon Pharma Oncology Presents Findings from Phase 2 Zella 201 Clinical Study Evaluating Investigational Agent Alvocidib in Patients with Acute Myeloid Leukemia at 62nd ASH Annual Meeting
•  
• Hyperlink InfoSystem Positioned As One Of The Top App Development Companies In Kuwait
•  
• Nor'easter to bring heavy rain, strong winds and snow to Northeast
•  
• Italian police break up migrant trafficking ring, arrest 19
•  
• Foul play suspected in death of Green Beret, Army vet at Fort Bragg
•  
• Biden expected to tap Vivek Murthy for surgeon general
•  
• Trump orders most of the 700 US troops out of Somalia
•  
• Grant Dorhout authors a new book - Modern Retirement Strategies: The Definitive Guide to Retiring Well
•  
• Community engagement app to make your city clean safe
•  
• SGS Reports on the Importance of Performance Testing in Changing Detergent Markets
•  
• EU Adds New Substance to Approved UV Filters in Cosmetic Products
•  
• Don Albach and Mike Russo co-author a new book - Modern Retirement Strategies: The Definitive Guide to Retiring Well
•  
• Rick Durkee, LUTCF® authors a new book - Modern Retirement Strategies: The Definitive Guide to Retiring Well
•  
• Genome Editing and Cellular Therapies Show Promise for Treating Blood Disorders, Cancers
•  
• AbbVie Presents Extended Follow-Up Data for Fixed Duration Treatment VENCLEXTA®/VENCLYXTO® (venetoclax) in Chronic Lymphocytic Leukemia (CLL)
•  
• Disease-Free Survival Data from CAPTIVATE Study Demonstrate Benefit of IMBRUVICA® (ibrutinib)-Based Regimen as Fixed Duration, First-Line Treatment for Patients with Chronic Lymphocytic Leukemia
•  
• Loxo Oncology at Lilly Announces Updated Data from the Phase 1/2 BRUIN Clinical Trial for LOXO-305 in Mantle Cell Lymphoma and Non-Hodgkin Lymphomas at the American Society of Hematology (ASH) Annual Meeting
•  
• IMBRUVICA® (ibrutinib) Plus VENCLEXTA®/VENCLYXTO® (venetoclax) Combination Shows High Rates of Disease-Free Survival One Year Post-Treatment in Previously Untreated Patients with Chronic Lymphocytic Leukemia (CLL)
•  
• Nashville ICU nurse shot dead in car while driving to work
•